# A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia

> **NCT00431873** · PHASE2 · COMPLETED · sponsor: **Mirati Therapeutics Inc.** · enrollment: 21 (actual)

## Conditions studied

- Lymphocytic Leukemia, Chronic

## Interventions

- **DRUG:** MGCD0103

## Key facts

- **NCT ID:** NCT00431873
- **Lead sponsor:** Mirati Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2015-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00431873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00431873, "A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT00431873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*